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Abstract
Background: Recent studies have suggested that deregulated AKT1 signaling is associated with schizophrenia. We
hypothesized that if this is indeed the case, we should observe both decreased AKT1 expression as well as deregulation of
AKT1 regulated pathways in Peripheral Blood Mononuclear Cells (PBMCs) of schizophrenia patients.
Objectives: To examine PBMC expression levels of AKT1 in schizophrenia patients versus controls, and to examine whether
functional biological processes in which AKT1 plays an important role are deregulated in schizophrenia patients.
Methods/Results: A case-control study, investigating whole-genome PBMC gene expression in male, recent onset (,5
years) schizophrenia patients (N=41) as compared to controls (N=29). Genes, differentially expressed between patients and
controls were identified using ANOVA with Benjamini-Hochberg correction (false discovery rate (FDR)=0.05). Functional
aspects of the deregulated set of genes were investigated with the Ingenuity Pathway Analysis (IPA) Software Tool. We
found significantly decreased PBMC expression of AKT1 (p,0.001, t=24.25) in the patients. AKT1 expression was decreased
in antipsychotic-free or -naive patients (N=11), in florid psychotic (N=20) and in remitted (N=21) patients. A total of 1224
genes were differentially expressed between patients and controls (FDR=0.05). Functional analysis of the entire
deregulated gene set indicated deregulated canonical pathways involved in a large number of cellular processes: immune
system, cell adhesion and neuronal guidance, neurotrophins and (neural) growth factors, oxidative stress and glucose
metabolism, and apoptosis and cell-cycle regulation. Many of these processes are associated with AKT1.
Conclusions: We show significantly decreased PBMC gene expression of AKT1 in male, recent-onset schizophrenia patients.
Our observations suggest that decreased PBMC AKT1 expression is a stable trait in recent onset, male schizophrenia
patients. We identified several AKT related cellular processes which are potentially affected in these patients, a majority of
which play a prominent role in current schizophrenia hypotheses.
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Introduction
Whole-genome gene expression studies using peripheral blood
cells, have yielded an extensive list of deregulated genes in
schizophrenia patients [1–5]. Although there are obvious limita-
tions to using these cells to investigate a CNS disease, they do
circumvent some of the confounding factors present in post-
mortem brain samples of schizophrenia patients, (e.g. life-long
exposure to psychotropic medication and drugs of abuse, and the
impact of long-term hospitalization). Moreover, lymphocytes can
be collected in the early phases of the disorder. Peripheral gene
expression can be informative about gene expression in the central
nervous system as whole blood shows significant gene expression
similarities with multiple central nervous system tissues, and the
expression levels of many classes of biologically relevant processes
are not significantly different between whole blood and prefrontal
cortex [6,7]. In patients with schizophrenia, a comparison of gene
expression profiles from brain tissue with profiles from peripheral
blood cells, identified genes that were common to both tissues,
confirming the validity of gene expression profiling of blood for
detecting schizophrenia biomarkers [3,4]. Specifically, the combi-
nation of gene expression data and bioinformatics provides an
opportunity to investigate perturbations in functional processes
over alterations in individual gene expression [8].
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several candidate risk-genes for schizophrenia (i.e. see Carter [9]).
Among these is AKT1, a member of the serine-threonine protein
kinase AKT gene family which includes three members (AKT1,
AKT2, and AKT3), that possess partially redundant functions and
contribute to several cellular functions including cell growth,
survival, and metabolism.
Gain or loss of AKT activity has been associated with several
human diseases, including cancer and type 2 diabetes [10,11]. An
influential article by Emamian et al. [12] showed a 68% reduction
of AKT1 protein levels in lymphocyte-derived cell lines of
schizophrenia patients, and presented several additional converg-
ing lines of evidence suggesting involvement of AKT1 in
schizophrenia, including disturbed prepulse inhibition in
AKT2/2 mice, decreased expression of AKT1 in post-mortem
brains of schizophrenia patients, and association of AKT1 variants
with schizophrenia.
Based on the findings of Emamian et al. [12], we hypothesized
that AKT1 expression might wel be decreased in PBMCs of
schizophrenia patients as compared to controls (hypothesis 1).
Furthermore we reasoned that reduced AKT1 expression in
patients should lead to deregulation of biological processes
in which AKT1 plays an important role (hypothesis 2). In addition,
we reasoned that if reduction of AKT1 was a signature of the
disease (either cause or consequence) rather than a response to
antipsychotics, it should also be deregulated in antipsychotic-free
or -naive patients (hypothesis 3).
Since all these hypotheses are dependent on finding different
AKT1 levels in PBMCs of patients, we first performed a pilot
study in Peripheral Blood Mononuclear Cells (PBMCs) to get a
feeling of the required power to proof or disproof this hypothesis.
Surprisingly, despite the small study (N=8 patients vs N=8
controls) we already observed a significant decreased AKT1
expression in medicated schizophrenia patients (pilot data are
summarized in supporting table S1). This formed the impetus
to perform a larger case-control study, investigating whole-genome
PBMC gene expression in schizophrenia patients as compared to
controls.
Schizophrenia is considered to be a syndrome with heteroge-
neous biological underpinnings. One such factor contributing to
heterogeneity are gender differences. Male patients with schizo-
phrenia have earlier onset, show more severe symptoms, leading to
more frequent hospital admission [13]. It has also been suggested
that estrogen activity may play a role in these observed male/
female differences. These phenomena may have impact on AKT1
activity. We therefore restricted inclusion to male patients only.
Methods
Subject selection
Male patients presenting with recent-onset schizophrenia at the
department of psychiatry of the Erasmus University Medical
Center, Rotterdam (EMC) were candidate to participate in the
study. The EMC operates an early recognition and treatment
clinic for patients with psychotic symptoms. Patients are referred
to the EMC by primary caretakers and general mental health care
facilities throughout the Rotterdam region (1.2 million inhabi-
tants), an industrialized area with a mixed population of Dutch
ancestry and immigrants, mainly from Northern-Africa, Turkey
and the Dutch West-Indies. Patients are referred to the EMC, with
acute psychotic symptoms. The EMC also offers prolonged
ambulatory treatment for patients with schizophrenia after
remission of acutely psychotic symptoms.
Eligible for inclusion were male patients diagnosed with
schizophrenia or schizophreniform disorder according to DSM
IV criteria after a Comprehensive Assessment of Symptoms and
History interview (CASH) [14] and by consensus between two
senior psychiatrists who were blind to the expression results at the
time of diagnosis. Additional criteria were recent onset (defined as
duration of illness ,5 yr) and age .15 and ,36 years. Clinical
symptom severity was assessed with the Positive And Negative
Syndrome Scale (PANNS).
Exclusion criteria were the presence of any somatic or
neurological disorders as investigated by routine clinical and
laboratory examination performed at admission, and abuse of
heroin, cocaine, or alcohol. Cannabis abuse was not an exclusion
criterion, to warrant the generalizability of our results, as patients
often use cannabis. Concomitant use of mood-stabilizers and/or
antidepressants was an exclusion criterion, as these agents are
known to influence AKT expression and/or phosphorylation
status.
We included stabilized patients from our outpatient clinic as
well as acutely psychotic recent-onset patients from our inpatient
clinic. In this way we would be able to assess the impact of variable
Duration of Illness (DUI) on AKT1 expression, and to assess the
effect of prolonged exposure to antipsychotic medication on
AKT1 expression. Moreover, inclusion of acutely psychotic,
never- or minimally treated patients enabled us to include
antipsychotic-naı ¨ve and –free patients (see also description of the
deferred consent procedure).
Age- matched controls were recruited from the students and
staff of the EMC medical school and hospital. The exclusion
criteria for the controls were the same as for the patients.
Additionally, the presence of psychiatric disorders in first-degree
relatives of the controls was also an exclusion criterion. Controls
were evaluated for the self-reported presence of somatic,
psychiatric or neurological disorders (either in the controls or in
their first-degree relatives), medication use, or the presence of drug
abuse. Cannabis abuse was, similar to the patients, not an
exclusion criterion.
All participating subjects were diagnosed and screened by a
single senior psychiatrist (NJMvB) who is trained in the CASH
interview, and final inclusion was reached based on consensus
between NJMvB and another senior psychiatrist (CR).
Inclusion criteria for the initial pilot study were similar to the
ones outlined in the previous paragraph; patients and controls
participating in the main study did not participate in the pilot
study.
Consent and deferred consent
All participating subjects provided written informed consent
after complete description of the study.
For those patients who were severely psychotic and too
disturbed to provide consent, a separate procedure was applied
in which informed consent was initially given by a first-degree
relative and final written consent was sought within six week from
the patients themselves (‘deferred consent’). Blood samples for
these patients were collected with a vacutainer system together
with the samples which are part of the regular clinical screening, so
no additional venipuncture was needed. Blood samples and data
from patients who withheld consent after six weeks were
destroyed. This procedure enabled us to include also the most
severely psychotic patients.
This study was approved (including the deferred consent
procedure) by the Erasmus University Medical Center Institution-
al Review Board and was conducted according to the declaration
of Helsinki.
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We paid meticulous attention to the processing of the blood
samples, isolation of RNA and preparation of the microarray in
order to minimize methodological variability. Samples from both
non-fasting patients and controls were taken around the same time
of the day (10–11 am), in the same room, with venipuncture
performed by the same (experienced) research nurse. From each
participant 30 ml of blood was drawn into heparinized tubes.
All blood samples were non-fasting and obtained between 10.00
and 121.00 am to minimize diurnal variation. Samples were
transported immediately to the laboratory facilities, which are
within walking distance from the clinical department. All
subsequent laboratory procedures, including biotinylation and
hybridization to the microarrays were performed by the same
analyst.
PBMCs were isolated by Ficoll gradient separation, started
within 20 minutes after the drawing of blood and performed with
minimum time variation. Cells were subsequently disrupted
(Qiashredder kit; Qiagen), and RNA was isolated (RNEasy
minikit; Qiagen) with an additional DNAse digestion step
(RNAse-free DNAse set; Qiagen),all according to the manufac-
turer’s protocol, diluted in nuclease-free water, and frozen at
280 C before use. Before freezing, RNA purity and quantity was
assessed with the NanoDrop ND-1000 spectrophotometer (Nano-
drop technologies). After thawing, the isolated RNA was
biotinylated into cRNA using the One-Cycle Target Labelling
and Control Reagents Kit (Affymetrix Co) according to the
manufacturer’s protocol. Before hybridization RNA quality and
integrity was assessed using the Agilent 2100 BioAnalyzer
(Agilent).
Biotinylated cRNA was hybridized to the Affymetrix Human
Genome U133 plus 2.0 GeneChip microarray containing
54,675 probe sets (Affymetrix Co). Each sample was individually
biotinylated and hybridized to an individual microarray. Biotiny-
lation was performed in batches with patients and controls both
being present in each of the batches. The arrays were scanned
and analyzed using Affymetrix Microarray Suite 4.2 software.
Scanning was performed in three batches. As samples from 43
patients and 29 controls were available for biotinylation and
scanning, patients and controls were present in an approximately
4:3 ratio in each batch.
All data is MIAME compliant; the raw data has been deposited
in the GEO database under accession number GSE27383,
scheduled for release July 1
st, 2013.
Statistical- and functional analysis
Raw intensities were normalized by quantile normalization.
Initial quality control investigated the effect of scanning date and
array intensities. Further data analysis was done using OmniViz
version 5.0 (Biowisdom), Partek, and R program. Minimum
thresholds were set at 30. Scanning data effects on expression
values were removed using Partek’s software package.
As hypothesis 1 states that AKT1 expression is altered in
PBMCs of patients, we investigated AKT1 expression levels
between patients and controls, using Students t-test (SPSS 16.0
statistical software). Schizophrenia patients frequently abuse
cannabis. This may influence AKT expression. As the control
group is not matched to the patients with respect to the use of
cannabis, we performed subgroup analysis within the patients to
explore the influence of cannabis use.
To identify transcripts that were differentially expressed
between patients and controls without an a priori hypothesis we
used analysis of variance (ANOVA) with Benjamini-Hochberg
correction for multiple comparisons, as provided by Partek’s
software package, with False Discovery Rate (FDR) set to 0.05. We
did not specify a minimal Fold-Change (FC) cut-off value, as it has
been shown that alterations in gene expression in AKT2/2 mice
can be significant and informative, though with minimal FC [15].
For both the pilot and the main study functional relationships
between genes which were differentially expressed between
patients and controls were investigated using the Ingenuity
Pathway Analysis software tool (IPA -Ingenuity SystemsH; www.
ingenuity.com). The IPA version of October 2006 and January
2009 were used for the pilot study and the main study respectively.
For canonical pathways we considered a p-value,0.05 as
significant.
Based on our hypothesis we specifically investigated the
presence of genetic networks and canonical pathways in which
AKT1 plays a role.
Table 1 gives a flow-chart overview of the analyses performed,
and in which tables the results of the analyses can be found.
Results
Subjects
We initially included 46 patients, and 30 controls in the study.
Of these, a total of 5 patients and 1 control were excluded: two
patients were excluded because of somatic disorders which were
identified after inclusion (one patient suffered from microcytic
anemia, one other patient of nephrotic syndrome); 1 patient and 1
control were not included because too little RNA was obtained,
and 2 more patients were excluded post-scanning because build-in
quality controls indicated poor quality of these samples.
The mean ages of the remaining 41 patients (23.02 (SD 4.03))
and 29 controls (23.90 (SD 4.08) years) were not significantly
different: p=0.378. Eleven patients were free of antipsychotic
medication for more than 2 weeks. See table 2 for the complete
patient characteristics.
AKT1 expression between patients and controls
We found decreased levels of expression of AKT1 (log-
transformed relative intensity values) in the patients (518.58 (SD
61.46) versus the controls (580.48 (SD 57.91)); t=24.250, df=68,
p,0.001; 95% CI 290.97; 232.84. The effect size of the
difference in the means is large (eta squared: 0.21).
Expression levels of AKT1 between acutely admitted (florid
psychotic) and remitted patients were not significantly different
(528.92 (SD 67.34 versus 508.73 (SD 55.13)), p=0.299.
Expression levels of AKT1 in antipsychotic-free patients (493.33
(SD 55.09) were not significantly different from the medicated
patients (526.89 (SD 63.06); t=1.449, df=39, p=0.155; 95% CI
212.25; 74.21, and still significantly different from the controls
(N=29; 580.48 (SD 57.91); t=24.220, df=38, p,0.001; 95% CI
2125.18; 243.96). Also, AKT1 expression in antipsychotic-naı ¨ve
patients (N=6) was not significantly different as compared to
medicated patients (N=30) (p=0.114). See figure 1.
Indeed, if any, AKT1 expression levels tended to be higher in
the medicated patients.
Also, AKT1 expression in patients using nicotine (N=26;
530.45 (SD 58.31)) was not significantly different from those who
did not smoke (N=15; 498.00 (SD 63.29): p=0.104. Neither was
AKT1 expression in patients using cannabis significantly different
as compared to patients not using cannabis (p=0.691). Also in
these cases, if any, patients with nicotine or cannabis abuse tended
towards higher level of AKT1 expression. Table 3 gives a
complete overview of AKT1 expression values in patient
subgroups.
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p=0.704), duration of iIlness (r: 0.242, p=0.155), PANSS
positive- (r: 0.120, p=0.501), or PANSS negative subscales (r:
0.129, p=0.466).
AKT isoforms and GSK-3A/3B expression
The AKT isoforms, AKT2 and AKT3, both showed a trend
toward decreased expression in the patients versus the controls.
AKT2: 255.83 (SD 28.32) versus 269.21 (SD 30.82), p=0.07;
AKT3: 240.88 (SD 36.60) versus 260.59 (SD 44.15), p=0.06. The
important downstream targets of AKT, GSK-3A (p=0.20) and
GSK-3B (p=0.97) did not show altered levels of expression
Significance analysis of the complete set of genes
ANOVA showed 1224 transcripts that were significantly
deregulated between patients and controls, after Benjamini-
Hochberg correction for multiple comparisons (FDR=0.05). See
supporting table S2 for the complete list of differentially
expressed genes. Of the 1224 deregulated transcripts, 272 were
upregulated, 952 were downregulated.
AKT1 is among these 1224 transcripts, so AKT1 remains
differentially expressed between patients and controls also after
Benjamini-Hochberg correction (p=0.0005).
Pathway analyses (see also table 1: flowchart of the
analyses)
Next, we investigated the involvement of the 1224 initially
identified probe sets in metabolic and signaling pathways using the
‘canonical pathway’ function of the IPA. This identified 35
canonical pathways in which more transcripts from the 1224
probe dataset participated than expected by chance (p,0.01), and
13 pathways using a more stringent criterion (p,0.001). Of the 35
deregulated pathways, AKT1 is involved in 20 pathways (57%).
Using the more stringent criterion of p,0.001 as significance
threshold, AKT1 is involved in 6 of the 13 deregulated pathways
(46%). Table 4 shows the deregulated canonical pathways, its
significance, and in which pathways AKT1 participates.
Further inspection shows that deregulated canonical pathways
are related to immune processes, cell adhesion and neuronal
guidance, neurotrophin signaling and (neural) growth factors,
oxidative stress and glucose metabolism, and apoptosis and cell-
cycle regulation.
Discussion
In this study we show decreased expression of AKT1 in PBMC’s
of young, recent-onset, male schizophrenia patients. To our best
knowledge this is the first confirmation of aberrant AKT1
expression in PBMC’s of schizophrenia patients after the initial
report by Emamian et al. [12] who investigated AKT1 protein
levels in cultured lymphocyte-derived cell lines with SDS-PAGE
and immunoblot analysis. We extend their findings by showing
that AKT1 is also decreased in non-cultured PBMC’s of
schizophrenia patients, collected in a clinical setting, and that
decreased expression is also observed in medication-free or -naive
patients.
In addition, we demonstrate significantly deregulated canonical
pathways in PBMC’s of patients, in approximately 50% of which
AKT1 is a key enzyme. We also show that deregulated canonical
pathways tend to cluster in families that are related to immune
processes, cell adhesion and neuronal guidance as well as apoptosis
and cell-cycle regulation, neurotrophin signaling and (neural)
growth factors, and oxidative stress and glucose metabolism.
Table 1. Flowchart description of the analyses.
Step: Procedure: Results can be found in:
1 Micro-array gene expression analysis
Quantile normalization of raw intensities
Expression threshold .30
Quality Control
2 patients removed because of outlying signal intensities
In final analysis: 41 patients and 29 controls Table 2
2 Test of hypothesis 1
Investigate PBMC AKT1 expression (t-test) in patients vs controls Table 3 and figure 1
Investigate AKT1 expression between patient subgroups (antipsychotic naı ¨ve/free vs medicated,
nicotine vs non-nicotine, cannabis vs non-cannabis)
Table 3 and figure 1
3 Identify all transcripts differentially expressed between patients and controls
Using the complete expressed set of transcripts:
Identify transcripts differentially expressed between patients and controls (ANOVA,
Benjamini-Hochberg correction for multiple comparisons, FDR,0.05)
supporting table S2
4 Upload differentially expressed transcripts into Ingenuity Pathway Analyzer (IPA)
5 Investigate general functional aspects of the set of differentially expressed transcripts Text, subheading ‘‘pathway analysis’’
6 Test of hypothesis 2
Investigate presence of the differentially expressed transcripts in metabolic and functional
processes using ‘canonical pathway’ function of the IPA
Table 4
Specifically investigate AKT1-related pathways Table 4
Initially included: 46 patients and 30 controls.
Excluded from analysis: 3 patients and 1 control (2 patients: somatic disorders discovered after inclusion; 1 patient and 1 control: insufficient RNA obtained).
Used for analysis: 43 patients and 29 controls.
doi:10.1371/journal.pone.0032618.t001
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florid psychotic patients, as well as in the remitted patients.
Importantly, AKT1 expression was decreased in both medicated
and unmedicated patients, indicating that decreased AKT expression
is not a consequence of medication. Antipsychotic medication and
nicotine or cannabis abuse were considered as possible confounders
affecting the expression of AKT1. However, we could not identify
significantly different levels of AKT1 expression between patients
using antipsychotic medication and those who were antipsychotic free
or –naı ¨ve, nor between drug abuse and non-abuse patients. If any,
patients using medication or drugs tended towards higher AKT1
expression levels. So, antipsychotic medication or substance use
probably cannot account for the decreased levels of PBMC AKT1
expression we found. Our study was, however, powered to find a
main effect for AKT1 expression between patients and controls, but
not for these subgroup analyses. So, our findings of decreased AKT1
expression in antipsychotic-naı ¨ve patients, and in those with cannabis
abuse, should be interpreted with caution.
We could not identify a correlation between AKT1 expression,
and age, duration of illness, and clinical symptom severity (PANSS
positive and negative subscales).
Taken together, our observations suggest that decreased PBMC
AKT1 expression is a stable trait in recent onset, male
schizophrenia patients.
The relationship between AKT1 and schizophrenia has been
previously described. Our findings significantly extend the work
done in association studies on AKT1 and schizophrenia by
showing decreased gene expression in a naturalistically obtained
patient sample. Since the initial report of deregulated AKT1 in
schizophrenia [12], several case/control samples and family
cohorts showed an association between schizophrenia and
AKT1 genetic variants [16–19]. However, as usual in association
studies in schizophrenia, a number of negative findings have also
been reported [20–24](for an updated compilation al all studies;
see http://www.schizophreniaforum.org/res/sczgene/geneover
view.asp?geneid=6). Also a number of post-mortem studies show
Table 2. Patient characteristics.
Patients (N=41) Controls (N=29)
Smoking yes: 26 (63.4%) Yes: 5 (17,2%)
no: 15 (36.6%) No: 24 (82,8%)
Cannabis abuse yes: 18 (43.9%) Yes: 2 (6,9%)
no: 23 (56.1%) No: 27 (93,1%)
Duration of illness (DUI) (weeks)
(N=36){
116.22 (SD 99.89) weeks
min-max: 1–250 weeks
median: 92.50 weeks
Ethnicity
European (mostly Dutch descent) 20 (48.8%) 24 (82,6%)
Surinamese/African descent 6 (14.6%) 1 (3,4%)
Cape Verdean 1 (2.4%) 0 (0,0%)
Surinamese/Hindustani 6 (14.6%) 1 (3,4%)
Moroccan/North African 2 (4.9%) 0 (0,0%)
Asian 1 (2.4%) 1 (3,4%)
Mixed 3 (7.3%) 2 (6,9%)
Could not be reliably assessed 2 (4.9%)
Antipsychotics used at study
entry
naive (mean age naive: 5.0 (SD 4.7) years) 6 (14.6%)
free.2 weeks, not naive (mean age
free.2 weeks: 25.2 (SD 3.9) years)
5 (12.2%)
total (free.2 weeks or naı ¨ve) 11 (26.8%)
haloperidol 9 (22.0%)
risperidone 1 (2.4%)
olanzapine 4 (9.8%)
quetiapine 1 (2.4%)
clozapine 15 (36.6%)
PANSS scores
total score 77.7 (SD 14.4)
positive subcale 18.5 (SD 6.6)
negative subscale 22.0 (SD 5.8)
general psychopathology 37.3 (SD 8.0)
{of 5 patients DUI could not be reliably assessed.
doi:10.1371/journal.pone.0032618.t002
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with schizophrenia [12,19,25].
AKT comprises three closely related isoforms AKT1, AKT2,
and AKT3. Although the AKT isoforms AKT2 and AKT3 did
not pass correction for multiple testing, an uncorrected t-test
showed a trend towards decreased expression for both AKT2
(p=0.07) and AKT3 (p=0.06). This observation suggests that
decreased expression may be present for all three AKT isoforms.
The three AKT isoforms were long thought to play redundant and
overlapping roles. Recent work however pointed to differential
roles played by AKT1 and AKT2 in a variety of cellular processes
[26]. AKT1 has predominantly been associated with cellular
survival and apoptosis, whereas AKT2 seems to be associated with
insulin signaling and glucose metabolism.
We did not find altered expression of the main downstream
target of AKT, GSK-3, in concordance with previous reports
[27,28].
From a conceptual perspective, the involvement of AKT in
schizophrenia is plausible. Generally, one of the major functions of
AKT is to promote growth-factor mediated cell survival and to
block programmed cell death or apoptosis [29–31]. Altered
apoptotic processes have repeatedly been proposed to underlie
schizophrenia, and are part of the influential so-called ‘neurode-
velopmental model of schizophrenia’ [32–34]. AKT is also a key
signaling enzyme downstream of dopamine D2 receptors [35–37].
Aberrant dopaminergic neuromodulation is one of the most well-
established findings in schizophrenia and is thought to underlie
psychotic phenomena as well as cognitive disorders present in
schizophrenia (i.e. see Kapur [38]).
Although the effect size of the difference in mean AKT1 values
between patients and controls is large by statistical standards, the
clinical utility of our finding is limited. The distribution of the data
(see figure 1) clearly shows overlap between patients and controls.
This may be due to biological heterogeneity underlying the
schizophrenia syndrome. The modern conceptualization of the
schizophrenia syndrome is that of a syndrome that originates from
multiple interwoven neurodevelopmental processes [39], in
interaction with environmental influences such as cannabis abuse
or living in an urban environment [40]. So, outlying values of
AKT1, as well as considerable overlap of values between patients
and controls, may be due to this heterogeneity.
Besides AKT1, we found a total of 1224 transcripts deregulated
between patients and controls in the main study. Of these, the
down-regulated transcripts greatly outnumber the up-regulated
ones, in an approximately 4:1 ratio. This finding is in line with
previous reports that (post-mortem) gene expression changes in
subjects with schizophrenia are predominantly characterized by
transcript reductions, rather than increases [41–43]. The magni-
tude of change however, although significantly altered, is limited
for the vast majority of transcripts, pointing towards only subtle
alterations in expression status. As PBMCs in schizophrenia do not
show overt pathology, subtle alterations in gene-expression are
what might be expected.
The results of the pathway analyses we performed show
aberrantly regulated processes in patients to be related to a
number of biological themes: immune processes, cell adhesion and
neuronal guidance, neurotrophins and (neural) growth factors,
oxidative stress and glucose metabolism, and apoptosis and cell-
cycle regulation (see table 4). A considerable number of
Figure 1. Scatter plots of PBMC AKT1 expression levels
between patients, patient subgroups, and controls. Cross-lines
show mean and standard error of the mean. * p,0.001 (independent
samples t-test).
doi:10.1371/journal.pone.0032618.g001
Table 3. Overview of mean levels of PBMC AKT1 expression levels (log-transformed relative intensity values) between patients and
controls and between patient subgroups.
Controls Patients (all)
Patients (acute)
vs patients
(stabilized)
Patients
(antipsychotic
naı ¨ve)
Patients
(antipsychotic
free.2
weeks)
Patients
(medicated)
Patients using
nicotine vs
non-nicotine
Patients using
cannabis vs non-
cannabis
(N=29) (N=41) (N=20, N=21) (N=6) (N=11) (N=30) (N=26, N=15) (N=18, N=23)
AKT1 expression
(mean 6 sd)
580.48657.91 518.58661.46* 528.92667.34 vs
508.73655.13{
481.81641.23{ 493.33655.09{ 526.72662.01* 530.45658.31 vs
98.00663.29{{
522.97665.88 vs
515.14659.05{{
*p,0.001 as compared to the controls (t-test).
{non-significant difference between acutely admitted patients vs stabilized patients.
{{non-significant difference between nicotine and non-nicotine.
{non-significant difference as compared to medicated patients.
{{non-significant difference between cannabis abuse vs non-cannabis abuse.
doi:10.1371/journal.pone.0032618.t003
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presence of an altered immune status in patients (pathways
which include AKT1 are in italics: Natural killer cell signaling,
Leucocyte Extravasation Signaling, T Cell Receptor Signaling,
Fc Epsilon RI Signaling, B Cell Receptor Signaling, IL-2 Signaling,
Xenobiotic metabolism Signaling, and IL-4 Signaling; see also
table 3). The presence of an immunological component in
schizophrenia has been hypothesized, based on several convergent
findings [42,44–48]. However, we want to point out that that the
finding of immune perturbations could well be an epiphenomenon
of the specific tissue under investigation.
The presence of deregulation of Integrin Signaling, Axonal guidance
Signaling, Ephrin receptor Signaling, and Neuregulin Signaling (table 3), all
of which are associated with neuronal outgrowth, cellular
patterning during development, and cell adhesion, combined with
the presence of deregulated, p53 Signaling, PTEN Signaling,
apoptosis Signaling)(see table 3) may indeed point to the presence
of aberrant neurodevelopmental processes. We also find the
neurotrophin/Trk signaling pathway deregulated, as well as some
other growth factor and cytokine related pathways (PDGF
Signaling, TGF-b Signaling, FGF Signaling, IGF-1 Signaling, VEGF
Signaling)(table 3). Neurotrophins are a specific subset of growth
factors, most notably among them Brain-Derived Neurotrophic
Factor (BDNF). There is an emerging body of converging evidence
that points to a relation between schizophrenia and disrupted
levels of BDNF, both in the central nervous system and in
peripheral blood (see [49,50] for a review). The biological
responses of neurotrophins after activating the neurotrophin/trk
pathway include among others proliferation and survival, and
axonal and dendritic growth and remodeling.
Finally, we find several deregulated canonical pathways which
may point towards the presence of altered insulin signaling and
oxidative stress (Inositol Phosphate Metabolism, Insulin Receptor Signaling,
NRF2-mediated oxidative stress response, IGF-1 Signaling, and Hypoxia
Signaling in the Cardiovascular System)(see table 3), pointing towards
alterations in glucose metabolism in schizophrenia, as have been
demonstrated to exist not only secondary to the use of
antipsychotics, but also in antipsychotic-naı ¨ve patients [25,51–53].
There are several strengths and limitations to our study. We
consider a specific strength the deferred consent procedure we
used, which enabled us to include severely disturbed, antipsychotic
free, or even –naı ¨ve patients. Furthermore, we rigorously
eliminated confounders during the laboratory procedures, such
as blood sampling by various staff members, inclusion at several
sites with associated multiple transport, storage and/or laboratory
procedures, and bench work by multiple scientists.
There are however, limitations of our study. First, we studied
PBMCs and the findings may not truly reflect changes in the
brain. Second, the majority of patients were on antipsychotic
medication. Several reports show that antipsychotics (haloperidol
as well as olanzapine and clozapine) influence AKT. However, the
majority of reports show that antipsychotics do not influence
expression levels of AKT, but only increase the phosphorylation
status of AKT, thus increasing AKT1 activity without influencing
its expression levels. This issue is extensively discussed in a recent
overview by Freyberg et al. [54]. Our results show that AKT1
expression is also decreased in the antipsychotic-free or -naı ¨ve
patients, in line with these findings.
We did not investigate patients with bipolar disorder or major
depression. Recent insights based on family and genetic studies
have suggested that especially bipolar disorder and schizophrenia
have a number of factors in common [55]. Data on the
relationship between AKT1 and bipolar disorder is scarce
however. Thiselton et al [18] measured mRNA levels of both
AKT1 and AKT2 isoforms in post-mortem brain tissue and found
a significant decrease in schizophrenia (AKT1) and in bipolar
disorder (AKT2). It may be fruitful to also investigate AKT levels
in peripheral tissue in bipolar disorder.
In conclusion, we show decreased PBMC gene expression of
AKT1 in schizophrenia patients, with a considerable effect size,
which allowed detection in two relative small cohorts. A large
number of AKT-related functions, processes and canonical
pathways are deregulated between patients and controls. A
majority of these have previously been associated with schizo-
phrenia. Specific attention merits the presence of an altered
Table 4. Canonical pathways deregulated between patients
and controls.
Canonical pathway Significance (IPA)
Natural killer cell signaling 0.00000036
SAP/JNK Signaling 0.00000283
Leucocyte Extravasation Signaling 0.00000304
T Cell Receptor Signaling 0.0000178
Huntington’s disease Signaling 0.0000334
Inositol Phosphate Metabolism 0.000105
Cell Cycle: G1/S Checkpoint Regulation 0.000114
Integrin Signaling 0.00019
Fc Epsilon RI Signaling 0.00021
B Cell Receptor Signaling 0.00025
Insulin Receptor Signaling 0.00054
JAK/Stat Signaling 0.001
p53 Signaling 0.001
PDGF Signaling 0.001
PTEN Signaling 0.001
Apoptosis Signaling 0.002
Nicotinate and Nicotinamide Metabolism 0.002
Axonal guidance Signaling 0.003
Ephrin receptor Signaling 0.004
Neurotrophin/Trk Signaling 0.004
PPARa/RXRa activation 0.005
NRF2-mediated oxidative stress response 0.008
TGF-b Signaling 0.01
Hypoxia Signaling in the Cardiovascular System 0.01
FGF Signaling 0.01
IL-2 Signaling 0.01
Wnt/b-catenin Signaling 0.01
ERK/MAPK Signaling 0.01
IGF-1 Signaling 0.01
Xenobiotic metabolism Signaling 0.02
IL-4 Signaling 0.03
Aryl Hydrocarbon Receptor Signaling 0.03
VEGF Signaling 0.03
Neuregulin Signaling 0.04
Protein Ubiquitination Pathway 0.04
Significance values as supplied by the IPA. Pathways in bold are pathways in
which AKT1 participates.
doi:10.1371/journal.pone.0032618.t004
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PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e32618immune status in the patients as well as a deregulated status of
genes associated with cell growth, cell guidance, cell adhesion,
(developmental) spatial patterning, and energy metabolism.
(Cultured) PBMCs may be useful tissue in which to investigate
aspects of the molecular biology of schizophrenia.
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